de Jong M - Search Results

1

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.

Ruigrok EAM, Tamborino G, de Blois E, Roobol SJ, Verkaik N, De Saint-Hubert M, Konijnenberg MW, van Weerden WM, de Jong M, Nonnekens J. Ruigrok EAM, et al. Among authors: de jong m, de blois e, de saint hubert m. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3627-3638. doi: 10.1007/s00259-022-05821-w. Epub 2022 May 12. Eur J Nucl Med Mol Imaging. 2022. PMID: 35556158 Free PMC article.

2

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

de Jong M, Kwekkeboom D, Valkema R, Krenning EP. de Jong M, et al. Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):463-9. doi: 10.1007/s00259-002-1107-8. Epub 2003 Feb 5. Eur J Nucl Med Mol Imaging. 2003. PMID: 12569416 Review.

3

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Breeman WA, et al. Among authors: de jong m. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. doi: 10.1007/s00259-003-1142-0. Epub 2003 Apr 4. Eur J Nucl Med Mol Imaging. 2003. PMID: 12677301

4

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Capello A, et al. Among authors: de jong m. Cancer Biother Radiopharm. 2003 Oct;18(5):761-8. doi: 10.1089/108497803770418300. Cancer Biother Radiopharm. 2003. PMID: 14629824

5

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

Konijnenberg MW, Bijster M, Krenning EP, De Jong M. Konijnenberg MW, et al. Among authors: de jong m. J Nucl Med. 2004 Jul;45(7):1260-9. J Nucl Med. 2004. PMID: 15235075 Free article.

6

Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.

Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Breeman WA, et al. Among authors: de jong m, de blois e, de jong mt. Nucl Med Biol. 2004 Aug;31(6):821-4. doi: 10.1016/j.nucmedbio.2004.03.008. Nucl Med Biol. 2004. PMID: 15246375

7

Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

Verwijnen S, Capello A, Bernard B, van den Aardweg G, Konijnenberg M, Breeman W, Krenning E, de Jong M. Verwijnen S, et al. Among authors: de jong m. Cancer Biother Radiopharm. 2004 Jun;19(3):285-92. doi: 10.1089/1084978041425098. Cancer Biother Radiopharm. 2004. PMID: 15285875

8

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. de Jong M, et al. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. J Nucl Med. 2005. PMID: 15653647 Free article.

9

Radiolabelling DOTA-peptides with 68Ga.

Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Breeman WA, et al. Among authors: de jong m, de blois e. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85. doi: 10.1007/s00259-004-1702-y. Epub 2005 Jan 18. Eur J Nucl Med Mol Imaging. 2005. PMID: 15655678

10

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Capello A, et al. Among authors: de jong m. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. doi: 10.1007/s00259-005-1877-x. Epub 2005 Jul 15. Eur J Nucl Med Mol Imaging. 2005. PMID: 16021448

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,111 results

Search Page